CLTEF News and Press, Calliditas Therapeutics AB - Class B From 07/20/23

2023-07-20 18:36:07 ET Summary We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales. Despite promising interim data, the market has y...

2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...

Calliditas Therapeutics AB (CALT) Q1 2021 Earnings Conference Call May 18, 2021 08:30 AM ET Company Participants Renée Lucander - CEO Richard Philipson - Chief Medical Officer Fredrik Johansson - CFO Andrew Udell - President, North America Conference Call Participants Yigal Nochomovitz -...

The following slide deck was published by Calliditas Therapeutics AB (publ) in conjunction with their 2021 Q1 earnings call. For further details see: Calliditas Therapeutics AB (publ) 2021 Q1 - Results - Earnings Call Presentation

Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...

Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...

Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM , April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm , are summoned to t...

EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy PR Newswire STOCKHOLM , April 23, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its lead p...

Calliditas strengthens its US Commercial and Medical Affairs Organization PR Newswire STOCKHOLM , March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks , PhD,...